Clinical Trials
Closed
Phase
Accrual
95%
SWOG Clinical Trial Number
SWOG-9300
A Randomized Phase II Evaluation of All Trans-Retinoic Acid (ATRA) with Interferon-Alfa 2a (IFN-alfa 2a) or All Trans-Retinoic Acid with Hydroxyurea (HU) in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
Research Committee(s)
Leukemia
Activated
10-01-1993
Closed
12-01-1999
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9142
Evaluation of Gallium Nitrate Continuous Infusion Therapy for Advanced Bladder Carcinoma
Research Committee(s)
Genitourinary Cancer
Activated
09-15-1993
Closed
02-01-1996
Closed
Phase
Accrual
91%
Published
SWOG Clinical Trial Number
SWOG-9314
Biologic Factors Predicting Response to Tamoxifen in Patients Registered to SWOG-8228, Ancillary
Research Committee(s)
Breast Cancer
Activated
09-01-1993
Closed
12-15-1995
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
SWOG-9043
Phase III Randomized Trial of Beta Carotene vs. Placebo in Prevention of Second Primaries in Stages I and II Head and Neck Cancer
Activated
09-01-1993
Closed
11-01-1994
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9326
Phase II Trial of Altretamine for Consolidation of Clinical Complete Response in Patients with Stage III Epithelial Ovarian Cancer
Research Committee(s)
Gynecologic Cancer
Activated
09-01-1993
Closed
07-01-1997
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9241
Evaluation of Topotecan in Colorectal Cancer, Phase II
Research Committee(s)
Gastrointestinal Cancer
Activated
07-15-1993
Closed
11-15-1994
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-9023
Cytogenetic and Flow Cytometric Analysis of Solid Tumors: Renal Cell Carcinoma: A Companion Study to SWOG-8949
Research Committee(s)
Genitourinary Cancer
Activated
07-01-1993
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9307
Extended Administration of Oral Etoposide And Oral Cyclophosphamide for the Treatment of Poor Prognosis Extensive Disease Small Cell Lung Cancer, Phase II Pilot
Research Committee(s)
Lung Cancer
Activated
07-01-1993
Closed
06-01-1996
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9106
Closed
Phase
Accrual
10%
SWOG Clinical Trial Number
SWOG-9213
A Phase II Evaluation of Fazarabine for Patients with "Poor Prognosis” Extensive Stage Small Cell Lung Cancer
Activated
06-15-1993
Closed
06-15-1994
Closed
Phase
Accrual
86%
Published
SWOG Clinical Trial Number
SWOG-9157
Trial of All Trans-Retinoic Acid in Hepatoma, Phase II.
Research Committee(s)
Gastrointestinal Cancer
Activated
06-01-1993
Closed
08-01-1994
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9230
Evaluation of Interleukin-4 (IL-4) in Disseminated Renal Cell Adenocarcinoma, Phase II
Research Committee(s)
Genitourinary Cancer
Activated
06-01-1993
Closed
05-01-1995
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9248
A Phase II Trial of Paclitaxel (Taxol ®) in Patients with Metastatic Refractory Carcinoma of the Breast
Research Committee(s)
Breast Cancer
Activated
06-01-1993
Closed
02-01-1994
Closed
Phase
Accrual
94%
Published
SWOG Clinical Trial Number
SWOG-9242
Evaluation of Taxotere in Small Cell Lung Carcinoma, Phase II
Research Committee(s)
Lung Cancer
Activated
05-01-1993
Closed
01-15-1997
Closed
Phase
Accrual
23%
SWOG Clinical Trial Number
SWOG-9120
Investigation of G-CSF and Trans-Retinoic Acid in the Treatment of Myelodysplastic Syndrome, Phase I
Activated
04-01-1993
Closed
07-01-1995
Closed
Phase
SWOG Clinical Trial Number
SWOG-9245
Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary
Research Committee(s)
Lymphoma
Activated
03-15-1993
Closed
Phase
Accrual
60%
Published
SWOG Clinical Trial Number
SWOG-9210
A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD-P to VAD-P/Quinine for Induction; (2) Randomization of Prednisone Dose Intensity For Remission Maintenance
Research Committee(s)
Myeloma
Activated
03-15-1993
Closed
09-01-1998
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9237
Evaluation of Topotecan in Resistant and Relapsing Multiple Myeloma, Phase II
Research Committee(s)
Myeloma
Activated
03-01-1993
Closed
02-15-1995
Closed
Phase
Accrual
58%
Published
SWOG Clinical Trial Number
SWOG-9246
A Phase II Evaluation of Taxol in Patients with Relapsed Non-Hodgkin's Lymphoma
Activated
03-01-1993
Closed
12-01-1995
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9126
A Controlled Trial of Cyclosporine as a Chemotherapy- Resistance Modifier in High Risk Acute Myeloid Leukemia, Phase III
Research Committee(s)
Leukemia
Activated
03-01-1993
Closed
03-01-1998